Expression of far upstream element binding protein 1 in B‑cell non‑Hodgkin lymphoma is correlated with tumor growth and cell‑adhesion mediated drug resistance

Huang,Yuejiao; Xu,Xiaohong; Ji,Lili; Wang,Yuchan; Wang,Shitao; Tang,Jie; Huang,Xianting; Yang,Xiaojing; He,Yunhua; He,Song; Cheng,Chun

doi:10.3892/mmr.2016.5718

Expression of far upstream element binding protein 1 in B‑cell non‑Hodgkin lymphoma is correlated with tumor growth and cell‑adhesion mediated drug resistance

Authors:
- Yuejiao Huang
- Xiaohong Xu
- Lili Ji
- Yuchan Wang
- Shitao Wang
- Jie Tang
- Xianting Huang
- Xiaojing Yang
- Yunhua He
- Song He
- Chun Cheng
View Affiliations

Affiliations: Department of Oncology, Affiliated Cancer Hospital of Nantong University, Nantong, Jiangsu 226361, P.R. China, Department of Pathology, Medical College, Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Immunology, Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Medical College, Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Pathology, Affiliated Cancer Hospital of Nantong University, Nantong, Jiangsu 226361, P.R. China
Published online on: September 6, 2016 https://doi.org/10.3892/mmr.2016.5718
Pages: 3759-3768

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cell adhesion‑mediated drug resistance (CAM‑DR) remains a major obstacle to the effectiveness of chemotherapeutic treatment of lymphoma. Far upstream element binding protein 1 (FBP1) is a multifunctional protein that is highly expressed in proliferating cells of several solid neoplasms; however, its expression and biological function in B‑cell lymphoma is largely unknown. FBP1 expression in both reactive lymphoid tissues and several B‑cell lymphomas, including follicular lymphoma and diffuse large B‑cell lymphoma were detected by immunohistochemistry analysis. FBP1 expression in B‑cell lymphoma was also associated with poor survival outcomes. Functionally, small interfering RNA‑mediated silencing of FBP1 was able to inhibit the proliferation of B‑cell lymphoma cells, resulting in G0/G1 phase cell cycle arrest. Furthermore, results of a cell adhesion assay demonstrated that adhesion to fibronectin or bone marrow stromal cells induced FBP1 expression, which in turn facilitated cell adhesion. Finally, FBP1 knockdown reversed CAM‑DR. These findings support a role for FBP1 in non‑Hodgkin lymphoma cell proliferation, adhesion and drug resistance, and may lead to the generation of a novel therapeutic approach targeting this molecule.

View Figures

View References

1	Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS and Tao J: Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 21:1521–1531. 2007. View Article : Google Scholar : PubMed/NCBI
2	Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G and Ye BH: Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 111:1515–1523. 2008. View Article : Google Scholar
3	Wang K, Jiang Y, Zheng W, Liu Z, Li H, Lou J, Gu M and Wang X: Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphoma. PLoS One. 8:e568292013. View Article : Google Scholar : PubMed/NCBI
4	Wang Y, Fei M, Cheng C, Zhang D, Lu J, He S, Zhao Y, Wang Y and Shen A: Jun activation domain-binding protein 1 negatively regulate p27 kip1 in non-Hodgkin's lymphomas. Cancer Biol Ther. 7:460–467. 2008. View Article : Google Scholar : PubMed/NCBI
5	Hang Q, Fei M, Hou S, Ni Q, Lu C, Zhang G, Gong P, Guan C, Huang X and He S: Expression of Spy1 protein in human non-Hodgkin's lymphomas is correlated with phosphorylation of p27 Kip1 on Thr187 and cell proliferation. Med Oncol. 29:3504–3514. 2012. View Article : Google Scholar : PubMed/NCBI
6	Zhao Y, Fei M, Wang Y, Lu M, Cheng C and Shen A: Expression of Foxo3a in non-Hodgkin's lymphomas is correlated with cell cycle inhibitor p27. Eur J Haematol. 81:83–93. 2008. View Article : Google Scholar : PubMed/NCBI
7	Lwin T, Lin J, Choi YS, Zhang X, Moscinski LC, Wright KL, Sotomayor EM, Dalton WS and Tao J: Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood. 116:5228–5236. 2010. View Article : Google Scholar : PubMed/NCBI
8	Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC, Sotomayor E, Dalton WS and Tao J: Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia. 23:170–177. 2009. View Article : Google Scholar
9	Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE and Nowakowski GS: Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol. 155:53–64. 2011. View Article : Google Scholar : PubMed/NCBI
10	Hazlehurst LA, Argilagos RF, Emmons M, Boulware D, Beam CA, Sullivan DM and Dalton WS: Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res. 66:2338–2345. 2006. View Article : Google Scholar : PubMed/NCBI
11	Westhoff MA, Zhou S, Bachem MG, Debatin KM and Fulda S: Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene. 27:5169–5181. 2008. View Article : Google Scholar : PubMed/NCBI
12	Weber A, Kristiansen I, Johannsen M, Oelrich B, Scholmann K, Gunia S, May M, Meyer HA, Behnke S, Moch H and Kristiansen G: The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer. 8:3692008. View Article : Google Scholar : PubMed/NCBI
13	Jang M, Park BC, Kang S, Chi SW, Cho S, Chung SJ, Lee SC, Bae KH and Park SG: Far upstream element-binding protein-1, a novel caspase substrate, acts as a cross-talker between apoptosis and the c-myc oncogene. Oncogene. 28:1529–1536. 2009. View Article : Google Scholar : PubMed/NCBI
14	Thiede B, Dimmler C, Siejak F and Rudel T: Predominant identification of RNA-binding proteins in Fas-induced apoptosis by proteome analysis. J Biol Chem. 276:26044–26050. 2001. View Article : Google Scholar : PubMed/NCBI
15	Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J, Chung HJ, Levens DL and Zörnig M: Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology. 50:1121–1129. 2009. View Article : Google Scholar : PubMed/NCBI
16	Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ and Dalton WS: Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 19:4319–4327. 2000. View Article : Google Scholar : PubMed/NCBI
17	Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA and Dalton WS: Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: Implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 69:1009–1015. 2009. View Article : Google Scholar : PubMed/NCBI
18	Naz E, Mirza T, Aziz S, Danish F, Siddiqui ST and Ali A: Frequency and clinicopathologic correlation of different types of non Hodgkin's lymphoma according to WHO classification. J Pak Med Assoc. 61:260–263. 2011.PubMed/NCBI
19	Filtenborg-Barnkob BE and Bzorek M: Expression of anaplastic lymphoma kinase in Merkel cell carcinomas. Hum Pathol. 44:1656–1664. 2013. View Article : Google Scholar : PubMed/NCBI
20	Li M, Yang X, Shi H, Ren H, Chen X, Zhang S, Zhu J and Zhang J: Downregulated expression of the cyclase-associated protein 1 (CAP1) reduces migration in esophageal squamous cell carcinoma. Jpn J Clin Oncol. 43:856–864. 2013. View Article : Google Scholar : PubMed/NCBI
21	Liu Y, Wang Y, Cheng C, Chen Y, Shi S, Qin J, Xiao F, Zhou D, Lu M, Lu Q and Shen A: A relationship between p27(kip1) and Skp2 after adult brain injury: Implications for glial proliferation. J Neurotrauma. 27:361–371. 2010. View Article : Google Scholar
22	Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, Lin Y, Yao J, Shi J, Kang T, et al: Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 23:316–331. 2013. View Article : Google Scholar : PubMed/NCBI
23	Malz M, Weber A, Singer S, Riehmer V, Bissinger M, Riener MO, Longerich T, Soll C, Vogel A, Angel P, et al: Overexpression of far upstream element binding proteins: A mechanism regulating proliferation and migration in liver cancer cells. Hepatology. 50:1130–1139. 2009. View Article : Google Scholar : PubMed/NCBI
24	Chen M, Zhang J, Li N, Qian Z, Zhu M, Li Q, Zheng J, Wang X and Shi G: Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS One. 6:e255642011. View Article : Google Scholar : PubMed/NCBI
25	Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, Muley T, Meister M, Hoffmann H, Penzel R, et al: Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res. 69:2234–2243. 2009. View Article : Google Scholar : PubMed/NCBI
26	Ding Z, Liu X, Liu Y, Zhang J, Huang X, Yang X, Yao L, Cui G and Wang D: Expression of far upstream element (FUSE) binding protein 1 in human glioma is correlated with c-Myc and cell proliferation. Mol Carcinog. 54:405–415. 2015. View Article : Google Scholar
27	Burger JA, Ghia P, Rosenwald A and Caligaris-Cappio F: The microenvironment in mature B-cell malignancies: A target for new treatment strategies. Blood. 114:3367–3375. 2009. View Article : Google Scholar : PubMed/NCBI
28	Fei M, Hang Q, Hou S, He S and Ruan C: Adhesion to fibronectin induces p27(kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells. Mol Cell Biochem. 386:177–187. 2014. View Article : Google Scholar
29	Fei M, Hang Q, Hou S and Ruan C: Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells. Int J Hematol. 98:446–455. 2013. View Article : Google Scholar : PubMed/NCBI
30	Yagi K, Yamamoto K, Umeda S, Abe S, Suzuki S, Onishi I, Kirimura S, Fukayama M, Arai A, Kitagawa M and Kurata M: Expression of multidrug resistance 1 gene in B-cell lymphomas: Association with follicular dendritic cells. Histopathology. 62:414–420. 2013. View Article : Google Scholar : PubMed/NCBI
31	Kurtova AV, Tamayo AT, Ford RJ and Burger JA: Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): Importance for interactions with the stromal microenvironment and specific targeting. Blood. 113:4604–4613. 2009. View Article : Google Scholar : PubMed/NCBI
32	Guan C, Shi H, Wang H, Zhang J, Ni W, Chen B, Hou S, Yang X, Shen A and Ni R: CtBP2 contributes to malignant development of human esophageal squamous cell carcinoma by regulation of p16INK4A. J Cell Biochem. 114:1343–1354. 2013. View Article : Google Scholar
33	Tjin EP, Groen RW, Vogelzang I, Derksen PW, Klok MD, Meijer HP, van Eeden S, Pals ST and Spaargaren M: Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood. 107:760–768. 2006. View Article : Google Scholar
34	Fernandez-Vidal A, Ysebaert L, Didier C, Betous R, De Toni F, Prade-Houdellier N, Demur C, Contour-Galcéra MO, Prévost GP, Ducommun B, et al: Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia. Cancer Res. 66:7128–7135. 2006. View Article : Google Scholar : PubMed/NCBI
35	Wang Y, Huang Y, Xu X, Tang J, Huang X, Zhu J, Liu J, Miao X, Wu Y, Yang F, et al: Expression of small glutamine-rich TPR-containing protein A (SGTA) in Non-Hodgkin's Lymphomas promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR). Leuk Res. 38:955–963. 2014. View Article : Google Scholar : PubMed/NCBI
36	He S, Huang Y, Wang Y, Tang J, Song Y, Yu X, Ma J, Wang S, Yin H, Li Q, et al: Histamine-releasing factor/translationally controlled tumor protein plays a role in induced cell adhesion, apoptosis resistance and chemoresistance in non-Hodgkin lymphomas. Leuk Lymphoma. 56:2153–2161. 2015. View Article : Google Scholar